|
|
2014年：
-
Jiaojiao Xu, Siyuan Wang, Ye Chen, Guangping Chen, Zaiquan Li, Xueyan Shao, Liang Li, Wei Lu, Tianyan Zhou*(2014) Dopamine D1 receptor activation induces dehydroepiandrosterone sulfotransferase (SULT2A1) in HepG2 cells. Acta Pharmacol Sin. In press. (IF= 2.354)
-
Xingang Li, Zhigang Zhao, Liang Li, Tianyan Zhou*, Wei Lu*(2014) Pharmacokinetics, in vitro and in vivo correlation, and efficacy of exenatide microspheres in diabetic rats. Drug Deliv. Early Online. (IF= 2.015)
-
Xiwei Ji, Runtao Li, Zaiquan Li, Liang Li, Xueyan Shao, Siyuan Wang, Yin Yuan, Tianyan Zhou*, Wei Lu*(2014) Inhibition of autophosphorylation of EGFR plays an important role in the anti-breast cancer efficacy of a dithiocarbamate derivative TM208. Acta Pharmacol Sin. 35:239–247. (IF= 2.354)
-
Yu-Ping Yu , Qi Wang , Ying-Chun Liu*, Ying Xie*（2014），Molecular basis for the targeted binding of RGD-containing peptide to integrin aVb3. Biomaterials, 35(5):1667-1675. (IF=7.604).
-
Hua Zhang, Xueqing Wang, Wenbing Dai, Richard A. Gemeinhart, Qiang Zhang, Tonglei Li. (2014) Pharmacokinetics and treatment efficacy of camptothecin nanocrystals on lung metastasis. Mol. Pharm. 11(1):226-233 (IF= 4.57)
-
Zhen-Zhen Yang, Jing-Quan Li, Zhan-Zhang Wang, Da-Wen Dong, Xian-Rong Qi*Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas.Biomaterials 35 (2014) 5226-5239.
-
Kai Wu, Zhan-Zhang Wang, Dan Liu, Xian-Rong Qi*.Pharmacokinetics, brain distribution, release and blood–brain barrier transport of Shunaoxin pills. J Ethnopharmacology. 151 (2014) 1133–1140.
-
Tingting Meng, Jingquan Li, Xianrong Qi*. Preparation and evaluation of lipidmatrix nanocarrier codelivery gene and sensibilizer to elevate docetaxel antitumor. J. Chin. Pharm. Sci. 2014, 23 (3), 145–152.
-
Ling-Ran Du, Xiao-Jing Lu, Hai-Tao Guan, Yong-Jie Yang, Meng-Jie Gu, Zhuo-Zhao Zheng, Tian-Shi Lv, Zi-Guang Yan, Li Song, Ying-Hua Zou, Nai-Qi Fu, Xian-Rong Qi, Tian-Yuan Fan* (2014) Development and evaluation of liquid embolic agents based on liquid crystalline material of glyceryl monooleate.Int J Pharm. 471: 285– 296. (IF 3.867)
-
Xueqing Wang, Suxin Li, Yujie Shi, Xingxing Chuan, Ji Li, Ting Zhong, Hua Zhang, Wenbing Dai, Bing He, Qiang Zhang*(2014) The development of site-specific drug delivery nanocarriers based on receptor mediation. Journal of Controlled Release. Early on line (IF 7.633)
-
Jingkai Lu, Xingxing Chuan, Hua Zhang, Wenbing Dai, Xinglin Wang, Xueqing Wang*, Qiang Zhang* (2014) Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: Preparation and comparison with other paclitaxel systems in vitro and in vivo.Int J Pharm..471 (1-2): 525-35. (IF 3.458)
-
Ju RJ, Li XT, Shi JF, Li XY, Sun MG, Zeng F, Zhou J, Liu L, Zhang CX, Zhao WY, Lu WL*(2014). Liposomes, modified with PTDHIV-1 peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer. Biomaterials. 2014 Aug;35(26):7610-21.
-
Li XY, Zhao Y, Sun MG, Shi JF, Ju RJ, Zhang CX, Li XT, Zhao WY, Mu LM, Zeng F, Lou JN,Lu WL*(2014).. Multifunctional liposomes loaded with paclitaxel and artemether for treatment of invasive brain glioma.Biomaterials. 2014 Jul;35(21):5591-604.
-
Wenjing Li, Xinru Li, Yajie Gao, Yanxia Zhou, Shujin Ma, Yong Zhao, Jinwen Li, Yan Liu*, Xinglin Wan, Dongdong Yin. The Inhibition Mechanism of P-glycoprotein Mediated Efflux by mPEG-PLA and Influence of PLA Chain Length on P-glycoprotein Inhibition Activity. Molecular Pharmaceutics, 2014, 11:71-80. (IF=4.57)
-
Wenbing Dai, Fang Yang, Ling Ma, Yuchen Fan, Bing He, Qihua He, Xueqing Wang, Hua Zhang, Qiang Zhang (2014) Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer. Biomaterials. 35(20):5347-5358. (IF7.604)
-
Zhaoming Guo, Bing He, Hongwei Jin, Haoran Zhang, Wenbing Dai, Liangren Zhang, Hua Zhang, Xueqing Wang, Jiancheng Wang, Xuan Zhang, Qiang Zhang*. (2014) Targeting efficiency of RGD-modified nanocarriers with different ligand intervals in response to integrin αvβ3 clustering. Biomaterials, 35(23):6106-6117.(IF:7.604)
-
Chao Qin, Bing He, Wenbing Dai, Zhiqiang Lin, Hua Zhang, Xueqing Wang, Jiancheng Wang, Xuan Zhang, Guangji Wang, Lifang Yin, Qiang Zhang. (2014) The impact of a chlorotoxin-modified liposome system on receptor MMP-2 and the receptor-associated protein ClC-3. Biomaterials, 35(22):5908-5920. (IF:7.604)
-
Wenbing Dai, Fang Yang, Ling Ma, Yuchen Fan, Bing He, Qihua He, Xueqing Wang, Hua Zhang, Qiang Zhang. (2014) Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer. Biomaterials, 35(20):5347-5358.(IF:7.604)
-
DefuCai, Wei Gao, Bing He, Wenbing Dai, Hua Zhang, Xueqing Wang, Jiancheng Wang; Xuan Zhang; Qiang Zhang. (2014) Hydrophobic penetrating peptide PFVYLI-modified stealth liposomes for doxorubicin delivery in breast cancer therapy. Biomaterials, 35(7):2283-2294.(IF:7.604)
-
Hua Zhang, Xueqing Wang, Wenbing Dai, Richard A. Gemeinhart, Qiang Zhang*, Tonglei Li. (2014) Pharmacokinetics and treatment efficacy of camptothecinnanocrystals on lung metastasis. Molecular Pharmaceutics. 11(1):226-233，(IF:4.57)
-
Zhiqiang Lin, Wei Gao, Hongxiang Hu, KunMa , Bing He ,Wenbing Dai, XueqingWang,JianchengWang , Xuan Zhang , Qiang Zhang*. (2014) Novel thermo-sensitive hydrogel system with paclitaxel nanocrystals:High drug-loading, sustained drug release and extended local retentionguaranteeing better efficacy and lower toxicity. Journal of Controlled Release, 174 : 161–170 (IF:7.633)
-
Feng Q, Yu MZ, Wang JC*, Hou WJ, Gao LY, Ma XF, Pei XW, Niu YJ, Liu XY, Qiu C, Pang WH, Du LL, Zhang Q. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles. Biomaterials. 2014 Mar; 35(18):5028-38.(IF:7.604)
-
Gao LY, Liu XY, Chen CJ, Wang JC*, Feng Q, Yu MZ, Ma XF, Pei XW, Niu YJ, Qiu C,Pang WH, Zhang Q. Core-Shell type lipid/rPAA-Chol polymer hybrid nanoparticles for in vivo siRNA delivery.Biomaterials. 2014 Feb;35(6):2066-78.(IF:7.604)
|
| |
